Reneo Pharmaceuticals (Reneo Pharmaceuticals) Operating Cash Flow per Share : $-2.31 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Reneo Pharmaceuticals Operating Cash Flow per Share?

Reneo Pharmaceuticals's operating cash flow per share for the three months ended in Mar. 2024 was $-0.63. Reneo Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.31.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -39.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Reneo Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

RPHM' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -39.4 Med: -22.9 Max: -6.4
Current: -39.4

During the past 5 years, Reneo Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was -6.40% per year. The lowest was -39.40% per year. And the median was -22.90% per year.

RPHM's 3-Year OCF Growth Rate is ranked worse than
85.08% of 1233 companies
in the Biotechnology industry
Industry Median: 3.5 vs RPHM: -39.40

Reneo Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Reneo Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reneo Pharmaceuticals Operating Cash Flow per Share Chart

Reneo Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-1.61

-0.77

-2.09

-1.93

-2.08

Reneo Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial													-0.36	-0.53	-0.56	-0.59	-0.63

Competitive Comparison of Reneo Pharmaceuticals's Operating Cash Flow per Share

For the Biotechnology subindustry, Reneo Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reneo Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reneo Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Reneo Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Reneo Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Reneo Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-63.682	/	30.676
	=	-2.08

Reneo Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-21.014	/	33.421
	=	-0.63

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.31

Reneo Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Reneo Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Reneo Pharmaceuticals (Reneo Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reneo Pharmaceuticals Inc (NAS:RPHM) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

18575 Jamboree Road, Suite 275-S, Irvine, CA, USA, 92612

Website

https://www.reneopharma.com

Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

Executives

Ashley Hall	officer: Chief Development Officer	C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Niall O'donnell	director	C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Michael Cruse	officer: Senior VP, Corporate Operation	C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jennifer Lam	officer: VP of Finance & Administration	C/O RENEO PHARMACEUTICALS, INC., 18575 JAMBOREE ROAD, SUITE 275-S, IRVINE CA 92612
Paul W. Hoelscher	director	1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Vineet R. Jindal	officer: Chief Financial Officer	C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Gregory J. Flesher	director, officer: President and CEO	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Bali Muralidhar	director	C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Wendy S. Johnson	officer: Chief Development Officer	800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Rivervest Venture Fund Iii (ohio), L.p.	10 percent owner	11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Rivervest Venture Fund Iii, L.p.	10 percent owner	7733 FORSYTH BOULEVARD, ST. LOUIS MO 63105
Stacey Denenberg Seltzer	director	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106